[Effect of 6-month S-methylmethionine intake on the quality of life and dyspepsia symptoms in patients with chronic gastritis].

S-methylmethionine (methylmethionine sulfonium chloride), better known as vitamin U, is a metabolic substrate that affects many metabolic processes in the human organism. Since its discovery, a large number of studies has been produced demonstrating its safety and effectiveness in various diseases, especially in diseases of the gastrointestinal tract. The purpose of the study was to evaluate the effect of methylmethionine sulfonium chloride (vitamin U) intake on the symptoms of dyspepsia and the quality of life of patients with chronic gastritis. Material and methods. The study included 37 patients (21 men and 16 women) aged 35-60 years with chronic gastritis of various etiologies. After inclusion in the study, all patients were prescribed S-methylmethionine at a dose of 300 mg per day. Clinical manifestations of dyspepsia were assessed using the GSRS questionnaire (Gastrointestinal Symptom Rating Scale), quality of life was assessed using the SF 36 questionnaire. The survey was conducted before the start of the therapy, after 3 and 6 months of complex diet therapy. Results. The most pronounced manifestations were dyspeptic (from 3 to 9 points) and diarrheal syndromes (from 2 to 5 points). Other indicators of the GSRS scale did not exceed 4 points. The total score was 15 points. By the 3rd month of therapy, there was a statistically significant decrease in the total score to 9 points (p<0.05). By the 6th month of therapy, the total GSRS score averaged 5.5 points (p<0.05). According to the SF 36 questionnaire, by the end of the 3rd month of therapy, indicators such as PF - physical functioning, BP - Bodily pain and SF - social functioning improved. By the end of the 6th month of therapy, several other indicators also improved (RP - role-physical functioning, GH - general perception of health, VT - viability, RE - Role-Emotional; MH - mental health) (p<0.05). Conclusion. The study showed that the appointment of dietary supplements containing methylmethionine sulfonium chloride at a dose of 300 mg per day helps to reduce the severity of dyspeptic symptoms in patients with chronic gastritis and their quality of life.

The Mechanism of Action of Ethoxidol on Oxidative Stress Indices in Heart Failure and Hypotension.

The aim of the investigation was to study the effect of 2-ethyl-6-methyl-3-hydroxypyridine malate (Ethoxidol) on the concentration of oxidative stress metabolites in patients with chronic heart failure (CHF) and hypertension. MATERIALS AND METHODS: 126 patients with FC I-III CHF have been examined. In addition to their individual therapy these patients received intravenous infusions of Ethoxidol. Blood content of 2,3-diphosphoglycerate (2,3-DPG), oxygen tension (рО2), pH, concentration of total peroxides, lactate, and aldosterone were identified. 2,3-DPG levels (g/L erythrocytes) in whole blood samples were determined by an enzyme assay using the reagent kit (Rosh, Germany), values of рО2, рСО2, рН, lactate in the venous blood were measured using gas analyzer Stat Profil pHOx Ultra (Nova Biomedical, USA). Indices of oxidative stress, i.e. the concentration of plasma total peroxides, were investigated by ELISA using OxyStat kit (Biomedica, Austria). Peripheral venous blood samples were collected from all patients before and 6 days after the daily intravenous Ethoxidol infusion. RESULTS: In patients with FC I, II, III CHF, on day 7 after intravenous Ethoxidol infusion at a dose of 100 mg/day, statistically significant growth (p=0.0002) of PaO2 level by 15.7, 17.4, and 22.8%, respectively, was noted. In patients with FC I, II, III CHF in the group receiving standard therapy, statistically significant (p=0.002) reduction of 2,3-DPG level by 2.7, 2.4, and 4.0%, respectively, was registered. On day 7 after the infusion of Ethoxidol at a dose of 100 mg/day, its decrease by 5.7, 10.5, and 26.2%, respectively (p<0.0001), was also observed. CONCLUSION: The increased concentrations of active oxygen forms have been established to negatively affect various bodily functions and adversely influence the pathophysiology of numerous diseases. Application of antioxidants, including Ethoxidol presented by us in this article, may become a clue to the development of preventive measures for many serious diseases.

[Comparative study of inactivated cultured vaccines against tick-borne encephalitis manufactured in Russia and in Austria by the "Immuno" firm]. / Sravnitel'noe izuchenie inaktivirovannykh kul'tural'nykh vaktsin protiv kleshchevogo 7entsefalita otechestvennogo proizvodstva i proizvodstva firmy "Immuno" (Avstriia).

Inactivated culture vaccine against tick-borne encephalitis (TBE) FSME-Immun-Inject produced in Austria ("Immuno") was compared to vaccine produced in the Institute of Poliomyelitis and viral encephalitis by immunological activity, safety, reactogenicity. In mice, no significant differences in protective activity of the vaccines were found when test-strains were diverse strains of TBE virus. Seroconversion in the sera from the vaccinated two times was not significantly different by the level of antibodies determined for both eastern and western serotypes of TBE virus.

[Characteristics of "Avaxim" hepatitis A vaccine produced by the firm "Pasteur Merrier" (results of field clinical trials)]. / Kharakteristika vaktsiny protiv gepatita A "Avaxim" proizvodstva firmy "Paster Mer'e" (rezul'taty polevykh klinicheskikh ispytanii).

Controlled field clinical trials of Avaxim vaccine from hepatitis A (Pasteur-Merrier-Connot) were carried out in adults and children aged 3-14 years to evaluate its reactogenicity and antigenic properties. The vaccine was weakly reactogenic both in adults and children. A single injection of the vaccine resulted after 1 month in the production of anti-HAV antibodies in 77.4% initially seronegative adults and 94.5% children. In adults the mean geometrical titer of antibodies was 95 mIU/ml and in children 165 mIU/ml, which was 5-8 times higher than the protective titer. These data recommend Avaxim vaccine for practical public health.

[A comparative evaluation of the immunogenicity and reactogenicity of recombinant vaccines against hepatitis B]. / Sravnitel'naia otsenka immunogennosti i reaktogennosti rekombinantnykh vaktsin protiv gepatita B.

Controlled epidemiological studies were carried out to evaluate two recombinant vaccines against hepatitis B of Cuban and Belgian production by the parameters of reactogenicity, safety and antigenic activity. Two groups of adult subjects (n = 73 each) and two groups of children (n = 30 each) were selected among those free from hepatitis B markers carrier state. The adults were given both preparations in a dose of 20 micrograms at intervals of 0-1-4 months, and the children received 10 micrograms at 0-1-2 months. The comparative studies showed both vaccines to be poorly reactogenic, safe and inducing anti-Hns in 80-100% of triply vaccinated subjects in titres within 100-500 IU. No statistically significant differences in the examined parameters were found in the two preparations tested.

[Comparative study of the reactivity, safety and immunogenicity of "Havrix" inactivated hepatitis A vaccine]. / Sravnitel;noe izuchenie reaktogennosti, bezopasnosti i immunoennosti inaktivirovannykh vaktsin protiv gepatita A "Havrix".

This paper sums up the results of controlled field clinical trials of adult and childhood variants of Harvix, inactivated vaccine from hepatitis A. The vaccine is weakly reactogenic and safe. After a single injection of Harvix-1440 vaccine to adults the percentage of seroconversions in previously seronegative individuals was 80.6%, with the mean geometrical antibody titer 119 mIU/ml. In children aged 3-10 years the percentage of seroconversions after a single injection of Harvix-720 vaccine was 100%, the mean geometrical of antibody titer being 427 mIU/ml. Results of laboratory control and field clinical trials recommend both variants of Harvix vaccine for prevention of hepatitis A in the Russian Federation.

[Comparative study of the immunogenicity of the inactivated hepatitis A vaccine Hep-A-in-vac from experimental and clinical data]. / Sravnitel'noe izuchenie immunogennosti inaktivirovannoi vaktsiny protiv gepatita A gep-A-in-vak po dannym éksperimental'nykh i klinicheskikh issledovanii.

Comparative analysis of the specific activities of various batches of Hep-A-in-Vac vaccine showed that the immunologic efficacy of the agent directly depended on the content of hepatitis A virus antigen in the vaccine dose. The results of studying the immunogenicity of the agent on volunteers are compatible with the results of experimental studies and indicate that the test of guinea pigs adequately assesses this characteristic. Assessment of the immunogenic properties of Hep-A-in-Vac prepared using improved technology indicates that Russian vaccine injected three times in a dose containing at least 40 U EIA ensures 87.5% seroconversion in adult seronegative volunteers with the mean geometrical titer of antibodies to hepatitis A virus equal to 683 mIU/ml.

[Evaluation of reactivity and immunogenicity of a cultured concentrated inactivated vaccine against hepatitis A "Hep-A-In-Vak"]. / Otsenka reaktogennosti i immunogennosti kul'tural'noi kontsentrirovannoi inaktivirovannoi vaktsiny protiv gepatita A "Gep-A-In-Vak".

Clinical trials of inactivated hepatitis A vaccine Hep-A-in-Vac demonstrated its specific safety and moderate reactogenicity, manifesting by short-term fibrillar twitching of musculus deltoideus at the site of injection. After a course of three immunizations 87.5% seronegative vaccines developed a high level of specific antibodies to hepatitis A virus with at least 100 reverse values of titers. In controls antibody titers remained seronegative in 90% cases. These data indicate evident immunologic activity of Hep-A-in-Vac vaccine.

[Russian recombinant vaccine against hepatitis B (results of controlled trials)]. / Otechestvennaia rekombinantnaia vaktsina protiv gepatita B (rezul'taty kontroliruemykh ispytanii).

Two yeast recombinant vaccines were compared: the Russian hepatitis B Combiotech vaccine in a dose of 20 mg and the Recombivax-HB vaccine in a dose of 10 mg manufactured in the USA (Merk, Sharp and Dohme Ltd.). Both agents were found safe and low reactogenic. After a course of 3 vaccinations with the Russian vaccine 92.5 to 97.5% subjects vaccinated after the 0-1-2 months and 0-1-6 months protocols had high levels of specific antibodies. In the group vaccinated with the American vaccine, antibodies to HBsAg were found in the sera of 95 to 100% subjects. These results demonstrate high immunological activity of both Russian and American vaccines.

[Reactogenicity of a group A and C meningococcal polysaccharide bivalent vaccine]. / Reaktogennost' meningokokkovoi polisakharidnoi divaktsiny gruppy A i C.

A total of 1 968 persons aged 18-20 years belonging to organized groups were immunized with different doses of polysaccharide meningococcal divaccine, groups A and C, by means of syringes and jet injectors under the conditions of a controlled epidemiological trial. Systemic reactions to the injection of the preparation were found to be absent. Local reactions manifested by inflammation, swelling and tenderness at the site of injection were faintly pronounced and disappeared in 48 hours, which is indicative of low reactogenicity of the preparation under study.

[A prospective study on mortality and incidence of myocardial infarct and stroke in male population 40-59 years of age at different risk levels]. / Prospektivnoe nabliudenie za smertnost'iu, chastotoi vozniknoveniiia infarkta miokarda i mozgovogo insul'ta v populiatsii muzhchin 40-59 let s razlichnym urovnem riska.

Prognostic value of tentatively identified levels of risk (coronary heart disease, risk factors, their combinations) for total, and cardiovascular mortality and myocardial infarction and stroke incidence was evaluated within the framework of the multifactorial coronary heart disease prevention programme. It was found that subjects without CHD in the presence of 3 risk factors or more represented a group at the same high risk for myocardial infarction and death as CHD patients without myocardial infarction, which requires that this population be comprehensively medically monitored. The multifactorial prevention programme has made it possible to reduce the level of a relative risk in subjects with CHD or those without CHD in the presence of 3 risk factors or more in the population of males aged 40-59 years. It may be thus expected mortality rates from chronic noncommunicable disease to be reduced among the general population.

[Comparative study of the diagnostic value of Brucella allergens in a controlled epidemiological trial]. / Sravnitel'noe izuchenie diagnosticheskoi tsennosti brutselleznykh allergenov v kontroliruemom épidemiologicheskon opyte.

The diagnostic value of 4 brucellar allergens used in Burnet's test has been studied in a controlled epidemiological trial. All these preparations have proved to be specific. According to the data of complex evaluation (taking into account reactogenicity, sensitivity, and specificity), the intradermal allergen consisting of the polysaccharide/protein complex extracted from acetone-dried cells of Brucella abortus vaccine strain 19 BA has shown the highest diagnostic effectiveness both in brucellosis patients and in persons immunized against brucellosis.

[Safety, reactogenicity and immunological activity of a group A meningococcal polysaccharide vaccine for children 1-4 years old]. / Bezvrednost', reaktogennost' i immunologicheskaia aktivnost' meningokokkovoi polisakharidnoi vaktsiny gruppy A dlia detei 1--4 let.

In the controlled trial carried out among children aged 1-4 years, the safety, reactogenicity and immunological potency of group A meningococcal polysaccharide vaccine produced at the Gabrichevskii Research Institute of Epidemiology and Microbiology (Moscow) were studied. The vaccine under test was introduced in two doses containing 15 and 25 micrograms of meningococcal polysaccharide. Both doses were shown to be safe, faintly reactogenic and immunologically potent. Systemic reactions were manifested by a transient rise in temperature to subfebrile levels in 19% and to 37.8-38.2 degrees C in 4.7% of the vaccinees. The temperature dropped to the normal level by the end of the first day following vaccination. At the site of injection skin hyperemia up to 2-3 cm in diameter was registered in 74% and up to 5-6 cm in diameter, in 6% of the vaccinees. Hyperemia disappeared on day 2 after vaccination. The production of antibodies to group A meningococcal polysaccharide occurred in response to both doses under test, and the elevated antibody level (in comparison to the initial one) was retained perceptibly longer in response to a dose of 25 micrograms; this dose, considering its low reactogenicity, was chosen as the optimal dose for children of the above age group.

[Prognostic significance of total blood cholesterol level and the possibility of dietary correction of hypercholesterolemia in the population]. / Prognosticheskaia znachimost urovnia obshchego kholesterina v krovi i vozmozhnost dieticheskoi korrektsii giperkholesterinemii v populiatsii.

In a population of males aged 40-59 years, a routine epidemiological survey was performed, which was followed by a 5-year follow-up to examine the mortality rates and incidence of myocardial infarction and stroke treated by an active prophylactic measure program (Group 1) and conventional regimen (Group 2). The total cholesterol levels of 260 mg/dl or more were found to be of highly prognostic value to death from all causes, largely cardiovascular diseases, to development of myocardial infarction, stroke, and to higher risk of fatal cases of the diseases. It was ascertained that it was difficult to modify the dietary habits in subjects of mature age. By the end of the fifth follow-up year, the examined patients from Group 1 showed a reduction in the mean level of total cholesterol and hypercholesterolemia rates, following by a decrease in total and cardiovascular mortality by 6.5 and 5.7%, respectively, the incidence of myocardial infarction and stroke and the risk of death from these complications becoming lower.

[Diagnosis of myocardial infarct with fatal outcome within the framework of multifactorial prevention of ischemic heart disease in Moscow]. / Diagnostika infarkta miokarda so smertel'nym iskhodom v ramkakh programmy mnogofaktornoi profilaktiki ishemicheskoi bolezni serdtsa, provedennoi v Moskve.

The death diagnosis of myocardial infarction (including acute heart failure) was recorded and verified on the basis of standard criteria during a 5-year implementation of the Program on Multifactorial Prevention of Coronary Heart Disease among males aged 40-59 years. The analysis demonstrated that the hyperdiagnosis of acute heart failure as a death cause was observed in 29.0% of cases, death being due to acute alcohol intoxication in 43% of all the inconsistent diagnoses.

[Test of the safety, reactogeneity and immunogeneity of live Flexner 2a and Sonne dysentery vaccine from spontaneous mutants, prepared in dragee form, in a controlled experiment on adults]. / Ispytanie bezvrednosti, reaktogennosti i immunogennosti zhivoi dizenteriinoi vaktsiny Fleksnera 2a i Zonne iz spontannykh mutantov, izgotovlennoi v vide drazhe, v kontroliruemom opyte na vzroslykh

Controlled experiment was conducted on 428 adult persons. A study was made of the reaktogenic properties and the immunological activity of live enteral dysentery vaccine Flexner 2a and Sonne from the spontaneous mutants developed at the N.F. Gamaleya Institute of Epidemiology and Microbiology. The vaccine is prepared in the form of sugar-coated pills covered with an acid-fast substance protecting from the gastric juice action. A single administration of the vaccine in a dose of up to 4 pills (6 to 8 X 10(9) live microbial cells) induced no general or local reactions. At the same time enteral administration of such low vaccine doses of the vaccine caused a significant accretion of specific hemagglutinins, including IgA, IgG, IgM antibodies in the serum, this pointing to the marked general and local immunological activity of the vaccine. Vaccine strains Flexner 2a and Sonne were isolated from 16 to 40% of the persons vaccinated, for the maximum period of 5 to 8 days. The isolated strains were avirulent when checked by the keratoconjuctival test.

[Reactogenicity and immunologic activity of live enteric Sonne dysentery vaccine from a spontaneous mutant]. / Reaktogennost' i immunologicheskaia aktivnost' zhivoi énteral'noi dizenteriinoi vaktsiny zonne iz spontannogo mutanta

Live dysentery Sonne vaccine from a spontaneous mutant proved to be practically areactogenic and specifically harmless in oral immunization of children aged from 7 to 13 years, in doses of from 3 to 25 milliard live microbial cells and in single and triple immunization schemes. Weak reactions of the gastro-intestinal tract were noted with the same frequency (1.7%) in children immunized with the vaccine and in children given placebo (2.2%). There proved to be a significant increase in the serum of the immunized persons of the level of specific hemagglutinins, and also of the IgA-and IgM-titers in 82% of the persons vaccinated; they persisted at a high level for 2 months. The appearance of IgA-antibodies in high titres in the persons vaccinated orally pointed to a marked local and general immunological activity of the live dysentery Sonne vaccine from the spontaneous mutant processing the capacity to survive in the intestine of children for a long time.

[Comparative study of the reactogenicity and immunogenicity of various doses of a chemical polysaccharide meningococcal vaccine administered by syringe and jet injector]. / Sravnitel'noe izuchenie reaktogennosti i immunogennosti razlichnykh doz khimicheskoi polisakharidnoi meningokokkovoi vaktsiny pri shpritsevom i struinom metodakh ee vvedeniia.

The article presents the results obtained in the comparative study of the reactogenicity and immunogenic potency of different doses of chemical polysaccharide meningococcal vaccine, type A, introduced with a syringe and a jet-injector. The preparation has been shown to possess low reactogenicity, high immunogenic potency and to produce a sufficiently pronounced intensity of postvaccinal immunity. The preparation is recommended for wide use in immunization of adults in a dose of 75 micrograms.

[Safety and reactogenicity of a group-A meningoccal polysaccharide vaccine for children 5 to 14]. / Bezvrednost' i reatkogennost' meningokokkovoi polisakhatridnoi vaktsiny gruppy A dlia detei 5-14 let.

The safety and reactogenicity of group A meningococcal polysaccharide vaccine prepared at the G. N. Gabrichevsky Research Institute for Epidemiology and Microbiology (Moscow) and intended for the immunization of children aged 5-14 years were studied. The data obtained in this study made it possible to characterize the preparation as safe and mildly reactogenic. Shifts in the blood formula registered 24 hours after the injection of the vaccine remained within the limits of physiological fluctuations. Subfebrile temperature persisting for 2 days was registered in some of the children aged 5-8 years. Local reaction in the form of hyperemia at the site of injection was insignificant. The optimum vaccination dose will be determined on the basis of the whole complex of the data presented in this work, as well as the data on the immunological activity of the preparation.

[Effect of multiple gamma globulin administration on the effectiveness of seroprophylaxis in hepatitis A]. / Vliianie mnogokratnogo vvedeniia gamma-globulina na éffektivnost' seroprofilaktiki gepatita A.

The data provided by immunological and epidemiological studies carried out to determine the influence of the multiple injections of 10% commercial gamma globulin on the level of antigamma globulin formation and, in this connection, on the effectiveness of the prophylaxis of hepatitis A are discussed. A sharp increase in the titers of antigamma globulin in persons receiving multiple gamma globulin injections is shown. The increased amount of antibodies to gamma globulin, appearing as the result of the multiple use of this preparation, decreases the effectiveness of the seroprophylaxis of hepatitis A.